A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...

The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

Vertex and CRISPR Therapeutics have won the backing of NICE for their gene-editing therapy Casgevy as a treatment for the blood disorder beta thalassaemia, a few months after turning it down for ...

I’ve been reviewing software for PCMag since 2008, and I still get a kick out of seeing what's new in video and photo editing software, and how operating systems change over time. I was ...

Casgevy, the first approved CRISPR gene-editing therapy, is picking up momentum in treating sickle cell disease and transfusion-dependent beta-thalassemia. The U.S. Food and Drug Administration ...

Are you reluctant to invest in stocks right now? That's understandable. Fear, uncertainty, and doubt have become the norm in early 2025 with rising stock market volatility. David Jagielski (Eli ...

The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA ...

Companies in the space often focus on the research and development of cutting-edge technologies such as gene editing or messenger RNA to power the medicines of tomorrow. The "if" in the above ...

After hours: 7:46:56 p.m. EDT Loading Chart for CRSP ...

This advertisement has not loaded yet, but your article continues below. The Prince Edward Island Regulatory and Appeals Commission (IRAC) announced a one-cent change to regular gas prices overnight, ...